MV140 Vaccine Helped People Remain UTI-Free For Years

New Delhi: Urinary Tract Infection (UTI) is a common bacterial infection said to be experienced by half of all women and one in five men. However, a study has shown that more than 50 per cent of people remained UTI-free for up to nine years who received the oral spray-based vaccine ‘MV140’.

According to the study published in the journal European Association of Urology, the MV140 vaccine is a potential alternative to antibiotic treatments. About 54 per cent of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported.

“Recurrent infections, needing short-term antibiotic treatment, develop in between 20 to 30 per cent of cases,” the study mentioned. This study, conducted by specialists at the UK’s Royal Berkshire Hospital, examined the safety and efficacy of the MV140 vaccine in 89 patients.

“Nine years after first receiving this new UTI vaccine, around half of participants remained infection-free. Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe,” said Dr Bob Yang, Consultant Urologist at the Royal Berkshire NHS Foundation Trust, who co-led the study.

MV140 vaccine was administered with two sprays of a pineapple-flavoured suspension under the tongue every day for three months in patients.

Developed by the Spain-based pharmaceutical company Immunotek, MV140 contains four bacterial species in a suspension with water. It is available off-license in 26 countries. In the research, 48 participants remained entirely infection-free during the nine-year follow-up.

The average infection-free period across the cohort was 54.7 months (four and a half years) – 56.7 months for women and 44.3 months, one year less, for men. 40 per cent of participants reported having repeat doses of the vaccine after one or two years, the study noted.

“This follow-up study reveals encouraging data about the long-term safety and effectiveness of the MV140 vaccine,” said Gernot Bonkat, Professor at the Alta Uro Medical Centre for Urology in Switzerland.

Related Posts

  • Pharma
  • May 25, 2024
  • 64 views
NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under…

  • Pharma
  • May 25, 2024
  • 75 views
Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Jaipur: To provide quality education in pharmacy institutes, the central government has prepared to end the duplicate system. Strict action will be taken against fake students and teachers in newly opened…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A Doctor diagnoses Mood of Voters in Delhi

A Doctor diagnoses Mood of Voters in Delhi

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research